Daniel Rader

Dr. Daniel Rader is a preventive cardiologist and a prominent researcher at the Perelman School of Medicine at the University of Pennsylvania. He is recognized for his contributions to understanding lipid metabolism and cardiovascular risk factors. Rader serves on the scientific advisory board for Novartis and has been vocal about the exciting advancements in treatments targeting lipoprotein(a), describing the reduction of Lp(a) levels as a significant breakthrough in cardiovascular medicine.